Outset Medical
140 hedge funds and large institutions have $308M invested in Outset Medical in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 36 increasing their positions, 43 reducing their positions, and 49 closing their positions.
0.36% more ownership
Funds ownership: 7.2% → 7.55% (+0.36%)
8% less funds holding
Funds holding: 152 → 140 (-12)
16% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 43
24% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 49
47% less capital invested
Capital invested by funds: $584M → $308M (-$276M)
91% less call options, than puts
Call options by funds: $273K | Put options by funds: $3.16M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$33.3M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$6.68M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$5.42M |
| 4 |
D.E. Shaw & Co
New York
|
+$4.19M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$2.5M |
Top Sellers
OM Hedge Fund Activity: Q4 2023 in Review
140 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Outset Medical (OM) for Q4 2023, worth a combined $308M — down 47% from $584M a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of OM and 37 opened new positions — a net loss of 12 holders — while 43 trimmed existing stakes and 36 added.
The largest buyer was Morgan Stanley, adding an estimated $33.3M. The largest seller was Champlain Investment Partners, exiting entirely with an estimated $21M sold.
- 140 institutional investors held Outset Medical (OM) as of Q4 2023, down from 152 in Q3 2023.
- Funds reported $308M of Outset Medical stock for Q4 2023, down 47% quarter-over-quarter.
- 37 funds opened new Outset Medical positions in Q4 2023 and 49 closed out, a net change of -12 holders.
- The largest Outset Medical buyer in Q4 2023 was Morgan Stanley, an estimated $33.3M added.
- The largest Outset Medical seller in Q4 2023 was Champlain Investment Partners, an estimated $21M sold.
Based on aggregated 13F filings for Q4 2023.